Inapparent infiltrations associated with vindesine administration

Publisher Website
Google Scholar
Abstract
Vindesine is des-acetyl vinblastine amide sulfate (Eldisine, Eli Lilly and Co.), an investigational derivative of the Vinca alkaloid, vinblastine. Initial phase I [human] results with vindesine have determined that myelotoxicity is dose-limiting and that, contrary to preclinical studies in animals, a neurotoxic potential is indeed present. Another phase I study also observed a rather high incidence of phlebitis (16%) and of cellulitis (10%), however, myelosuppression remained the dose-limiting toxicity. Because good clinical responses have been noted in lymphomas, leukemias and some solid tumors including breast cancer, the drug has a potential for wide utility. However, while several clinical responses were noted with vindesine, injections of the drug have been complicated by serious infiltration with atypically delayed presentation. The incidence and course of these infiltrations were described.

This publication has 1 reference indexed in Scilit: